New Amgen CEO must win investors with payouts, deals
Bob Bradway hasn’t even taken the helm at Amgen Inc (AMGN.O), but the clock is already ticking on how the world’s largest biotech will compete with rivals, including Big Pharma. Powerful value investors, who helped push up the stock 26 percent since it took a page from traditional drug companies last year with a dividend […]
Read More »Category : News
Public Opinion Mixed on Medical Device Firms
Source Generally, we confine ourselves to matters concerning the pharmaceutical industry. Every now and then, though, we tiptoe into related fields for a couple of reasons – there are overlapping regulatory issues or some of the biggest drugmakers also play in other sandboxes where their fortunes are affected. And so we thought it would be […]
Read More »Category : News
Dealing With Patient Adherance Problems….
Source Getting patients to take their meds is always a difficult proposition. Some folks are forgetful. Others are concerned with expenses or side effects. Then there are those patients who are reluctant to acknowledge their illness or are slightly suspicious of their healthcare provider. So what are drugmakers doing about the lack of patient adherence? […]
Read More »Category : News
Raw material woes for Pakistan could lead to swift exit for drugsmakers, says ABC
The American Business Council (ABC) has warned US drugsmakers working in Pakistan to brace themselves for supply chain disruptions as the Government imposes heavy delays on the process used to allocate raw materials to manufacturers.
Read More »Category : News
Analysts predict Covance cuts to align tox capacity with demand
Analysts expect Covance to cut toxicology capacity in response to continued weak demand for GLP services.
Read More »Category : News
Officials issue warning over fentanyl patches
U.S. health officials warned on Thursday about the sometimes deadly effect of overexposure to fentanyl painkiller patches, particularly for small children, saying at least 10 people have died and 12 hospitalized in the last 15 years. In a safety alert, the U.S. Food and Drug Administration said a majority of the 26 cases of accidental […]
Read More »Category : News
Novartis Dodges a Bullet from EMA
Source After months of uncertainty, the European Medicines Agency has recommended continued use of the Gilenya multiple sclerosis pill sold by Novartis, although the regulator did say the drug should carry stronger warnings about heart risks. Although the risks were known at the time of approval two years ago, the review was made in response […]
Read More »Category : News
FDA Looks to Buff Up Post-Marketing Safety Image
Source Continually on the defensive about its efforts to monitor drug safety, the FDA issued a report over the weekend that trumpets various undertakings to oversee medicines after they have reached the market. Its release comes just as Congress gears up to approve the latest version of the Prescription Drug User Fee Act, or PDUFA, […]
Read More »Category : News
Merck KGaA CEO: Must Significantly Reduce Costs, Slash Jobs
German pharmaceutical company Merck KGaA (MRK.XE) must significantly reduce costs and cut staff, Chief Executive Karl-Ludwig Kley said Friday at the company’s annual shareholder meeting. Merck’s personnel expenses have to be reduced notably, said Kley, without specifying. Personnel costs accounted for almost 40% of last year’s around EUR8 billion operating expenses, according to the CEO. […]
Read More »Category : News
Bankrupt Cetero Redoing Studies For Some Drugmakers?
Source Last summer, the FDA alerted the pharmaceutical industry that any clinical tests conducted between April 2005 and June 2010 by a contract research organization called Cetero Research may have to be reevaluated because two agency inspections and an outside audit found falsified data and manipulated samples (back story). So which companies need to have […]
Read More »Category : News
